Aetna modified CPB 1088 to cover clesrovimab-cfor (Enflonsia) for RSV prevention in eligible infants under commercial medical plans, effective December 4, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, published this updated Enflonsia coverage policy under CPB 1088 Aetna system. The primary billable code for clesrovimab-cfor is CPT 90382 (the 0.7 mL seasonal monoclonal antibody dose). If your practice or health system administers RSV immunization products to newborns and infants, this policy directly affects your charge capture, claim submission, and medical necessity documentation for the 2025–2026 RSV season.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Clesrovimab-cfor (Enflonsia) — CPB 1088 |
| Policy Code | CPB 1088 |
| Change Type | Modified |
| Effective Date | December 4, 2025 |
| Impact Level | High |
| Specialties Affected | Pediatrics, Neonatology, Obstetrics, Infectious Disease, Pediatric Cardiology |
| Key Action | Verify maternal RSV vaccine status before billing CPT 90382 — coverage depends on it |
Aetna Clesrovimab-cfor (Enflonsia) Coverage Criteria and Medical Necessity Requirements 2025
Aetna's clesrovimab-cfor coverage policy covers a single intramuscular injection of Enflonsia for RSV lower respiratory tract disease prevention in infants — but only under specific clinical conditions. The criteria are more layered than a simple age cutoff. Your billing team and clinical staff both need to understand the maternal vaccine interaction before billing CPT 90382.
The baseline criteria for infants under 8 months old entering their first RSV season:
Medical necessity is met when the infant is under 8 months old and one of these three maternal vaccine conditions applies:
| # | Covered Indication |
|---|---|
| 1 | The mother did not receive an RSV vaccine, or her status is unknown. |
| 2 | The mother received an RSV vaccine fewer than 14 days before delivery. |
| 3 | The mother received an RSV vaccine during a prior pregnancy (not the current one). |
In all three cases, the infant also must not have previously received any dose of clesrovimab-cfor, nirsevimab-alip (Beyfortus), or palivizumab (Synagis). Document this clearly in the record before billing. A prior dose of any of those products disqualifies the infant from coverage under this indication.
When the mother was vaccinated 14+ days before delivery:
This is where the policy gets complicated. Aetna follows CDC ACIP guidance that most infants don't need both maternal RSV vaccine protection and infant immunization. If the mother received the RSV vaccine (Pfizer's Abrysvo, bivalent RSVpreF) 14 or more days before delivery, the infant generally doesn't qualify — unless one of these clinical exceptions applies:
| # | Covered Indication |
|---|---|
| 1 | The mother has an immunocompromising condition and may not have mounted an adequate immune response. |
| 2 | The mother has HIV infection (ICD-10: B20), which is associated with reduced transplacental antibody transfer. |
| 3 | The infant had cardiopulmonary bypass, ECMO, or exchange transfusion, causing loss of RSV antibodies. |
| 4 | The infant has substantially increased risk for severe RSV disease — specifically hemodynamically significant congenital heart disease (ICD-10 range Q20.0–Q28.9), required ICU admission, or required oxygen at discharge (ICD-10: Z99.81). |
These exceptions require clinical judgment documented by the treating provider. Make sure that documentation is in the record before submitting a claim. A missing note is a direct path to claim denial.
The additional post-surgical dose:
Aetna also covers an additional Enflonsia dose for infants who undergo cardiac surgery involving cardiopulmonary bypass, ECMO, or exchange transfusion during or entering their first RSV season. The clinical rationale is sound — those procedures can deplete clesrovimab-cfor serum levels. The additional dose is covered as soon as the infant is stable post-surgery.
For reimbursement on additional doses, the documentation should explicitly reference the specific procedure and timing. Don't assume the claim will process without it.
Prior authorization requirements are not explicitly stated in this policy update, but the complexity of the eligibility criteria — especially the maternal vaccine status dependency — means you should verify coverage with Aetna before administering Enflonsia when the clinical picture is borderline. Call early. Don't let a coverage dispute land after the injection is already given.
Aetna Enflonsia Exclusions and Non-Covered Indications
Aetna is direct on this: all indications not explicitly listed in the criteria above are experimental, investigational, or unproven. There are no gray areas on this point.
That means off-label use in infants who don't meet the maternal vaccine criteria — or use in older children outside the first RSV season eligibility window — won't get covered. If a provider administers Enflonsia outside these criteria and your team submits the claim, expect denial.
The policy also draws a clear line between clesrovimab-cfor (this policy, CPB 1088) and two related products. For nirsevimab-alip (Beyfortus), refer to CPB 1038. For the maternal RSV vaccine (Abrysvo), refer to CPB 1027. Billing the wrong product code or confusing the clinical indications across these three policies is a real risk when multiple RSV prevention options are in play. Separate your charge capture workflows by product.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Infant <8 months, first RSV season, maternal RSV vaccine not given or unknown | Covered | CPT 90382, Z29.11 | Infant must not have received prior clesrovimab, nirsevimab, or palivizumab dose |
| Infant <8 months, maternal RSV vaccine given <14 days before birth | Covered | CPT 90382, Z29.11 | Same prior-dose exclusion applies |
| Infant <8 months, maternal RSV vaccine given in prior pregnancy | Covered | CPT 90382, Z29.11 | Same prior-dose exclusion applies |
| Maternal immunocompromising condition — possible inadequate immune response | Covered (provider clinical judgment) | CPT 90382, B20, Z29.11 | Applies when maternal vaccine was given ≥14 days before birth |
| Infant with HIV-positive mother (reduced transplacental antibody transfer) | Covered (provider clinical judgment) | CPT 90382, B20, Z29.11 | HIV diagnosis on maternal or infant record supports medical necessity |
| Infant who had cardiopulmonary bypass, ECMO, or exchange transfusion — RSV antibody loss | Covered (provider clinical judgment) | CPT 90382, Z29.11 | Document the specific procedure and timing |
| Infant with hemodynamically significant congenital heart disease or oxygen dependence at discharge | Covered (provider clinical judgment) | CPT 90382, Q20.0–Q28.9, Z99.81, Z29.11 | ICU admission or O2 requirement at discharge also qualifies |
| Additional dose post-cardiac surgery with bypass/ECMO/exchange transfusion | Covered | CPT 90382, Z29.11, Z95.1 | Administer when infant is stable; document surgical procedure |
| All other indications | Not Covered | — | Considered experimental, investigational, or unproven by Aetna |
Aetna Enflonsia Billing Guidelines and Action Items 2025
The effective date is December 4, 2025. Here's exactly what your team should do.
| # | Action Item |
|---|---|
| 1 | Update your charge capture to separate CPT 90382 from 90380 and 90381. CPT 90382 (0.7 mL dose) is the code Aetna covers when selection criteria are met. CPT 90380 (0.5 mL) and 90381 (1 mL) are listed as related codes but are not in the covered group under this policy. Bill the wrong dose code and you will get denied. Confirm which formulation your facility stocks and maps to 90382. |
| 2 | Add a maternal RSV vaccine status field to your pre-administration checklist. The coverage criteria hinge on whether the mother received Abrysvo, when she received it, and whether it was during the current or a prior pregnancy. If your nursing or clinical staff can't answer those questions at point of care, your billing team can't support the claim. Build the documentation requirement into your intake workflow now — before the RSV season accelerates. |
| 3 | Use ICD-10 Z29.11 as your primary encounter code for prophylactic Enflonsia administration. This code — "Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV)" — is the correct diagnosis code for RSV immunization billing. Add appropriate secondary codes based on the specific clinical indication: B20 for HIV, Q20.0–Q28.9 range for congenital heart disease, Z99.81 for oxygen dependence at discharge. |
| 4 | Bill the administration code correctly. CPT 96380 and 96381 are the specific administration codes for RSV monoclonal antibody by intramuscular injection. CPT 96372 is listed as a related code but is less specific. Check your payer contract and fee schedule — some payers reimburse administration separately from the drug, others bundle it. Confirm with Aetna before the claim goes out. |
| 5 | Document clinical judgment explicitly for the exception indications. When coverage depends on provider clinical judgment — maternal immunocompromise, reduced transplacental transfer, or increased infant RSV risk — the physician note needs to say so directly. "Provider assessed infant as at substantially increased risk for severe RSV disease due to hemodynamically significant congenital heart disease" is the kind of language that survives a medical necessity audit. "RSV prophylaxis administered" will not. |
| 6 | For post-surgical additional doses, create a separate charge entry with procedure documentation attached. The policy allows an additional dose after cardiac surgery with bypass or ECMO. Bill this as a separate encounter with documentation referencing the surgical procedure, the date of surgery, and the clinical rationale for the additional dose. ICD-10 Z95.1 (presence of aortocoronary bypass graft) may apply depending on the surgical history. |
| 7 | Do not bill Enflonsia and nirsevimab-alip (Beyfortus) for the same infant in the same RSV season. The policy explicitly states the infant must not have previously received a dose of clesrovimab-cfor, nirsevimab-alip, or palivizumab. If your system shows a prior Beyfortus claim for that patient, Enflonsia is not covered. Run a claims history check before administering and billing. |
If your patient mix includes a high volume of NICU discharges, infants with congenital heart disease, or HIV-positive mothers, talk to your compliance officer before December 4, 2025. The clinical judgment indications in this Aetna clesrovimab billing policy need internal documentation standards — and those standards should be set before the first claims go out, not after the first denials come back.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Clesrovimab-cfor (Enflonsia) Under CPB 1088
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 90382 | CPT | Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| B20 | Human immunodeficiency virus [HIV] disease |
| B97.4 | Respiratory syncytial virus as the cause of diseases classified elsewhere |
| Q20.0–Q28.9 | Congenital malformations of the circulatory system |
| Z29.11 | Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV) |
| Z95.1 | Presence of aortocoronary bypass graft |
| Z99.81 | Dependence on supplemental oxygen |
Get the Full Picture for CPT 90382
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.